NVO Earnings Date: Nov 4, 2026 — Novo Nordisk A/S
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is NVO's next earnings date?
Novo Nordisk A/S (NVO) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026 at 1:30 AM ET (before market open). The consensus estimate is EPS of $0.73 on revenue of $11.11B.
How did NVO do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), Novo Nordisk A/S posted EPS of -$0.01 versus the $0.81 estimate, a miss of 100.9%. Revenue was $0 against a $11.27B estimate. The stock's 1-day post-earnings move was -1.3%.
How much does NVO stock move after earnings?
NVO beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.3% (up or down) in the day after earnings.
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
🤖 AI Earnings Analysis
NVO’s 2026 reported-revenue outlook implies a 4%–12% decline from $48.17B, overshadowing its 33.14% margin and near-10× P/E.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | 0.81 | -0.01 | -100.86% | $0 | ❌ Miss | -1.32% | +2.77% | -6.49% |
| 2026-08-05 | 0.82 | 0.96 | +17.07% | $12.13B | ✅ Beat | +3.81% | +6.52% | +6.56% | |
| 2026-05-13 | Q1 2026 | 0.87 | -0.00 | -100.23% | $0 | ❌ Miss | -2.72% | -4.26% | -6.79% |
| 2026-02-04 | Q4 2025 | 0.89 | 1.00 | +12.36% | $12.34B | ✅ Beat | -6.17% | -2.34% | -22.33% |
| 2025-11-05 | Q3 2025 | 0.77 | 1.03 | +33.38% | $11.74B | ✅ Beat | +0.45% | +1.86% | -0.54% |
| 2025-08-06 | Q2 2025 | 0.93 | 0.91 | -2.15% | $11.68B | ❌ Miss | -3.91% | +5.41% | +19.82% |
| 2025-02-05 | Q4 2024 | 0.83 | 0.91 | +9.64% | $12.26B | ✅ Beat | +3.77% | +1.35% | +6.56% |
| 2024-11-06 | Q3 2024 | 0.88 | 0.90 | +2.27% | $10.50B | ✅ Beat | -4.33% | -2.79% | -1.19% |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2023 · $215.57B total · annual
| Segment | Share | Revenue | YoY | FY2022 | FY2023 |
|---|---|---|---|---|---|
| North America | 63.4% | $136.63B | +50.0% | $91.11B | $136.63B |
| EMEA | 23.6% | $50.87B | +15.0% | $44.24B | $50.87B |
| Rest of World | 13.0% | $28.08B | +10.5% | $25.40B | $28.08B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.